179 related articles for article (PubMed ID: 15758864)
1. Use of GNRH antagonists in reproductive medicine.
Merviel P; Najas S; Campy H; Floret S; Brasseur F
Minerva Ginecol; 2005 Feb; 57(1):29-43. PubMed ID: 15758864
[TBL] [Abstract][Full Text] [Related]
2. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
[TBL] [Abstract][Full Text] [Related]
3. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
4. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
5. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
[TBL] [Abstract][Full Text] [Related]
6. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
7. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
8. [The programming of IVF cycles with antagonists].
Hugues JN
J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S19-20. PubMed ID: 15643680
[TBL] [Abstract][Full Text] [Related]
9. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
Diedrich K; Diedrich C; Santos E; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
Hum Reprod; 1994 May; 9(5):788-91. PubMed ID: 7929723
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
12. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study.
Prapas N; Prapas Y; Panagiotidis Y; Prapa S; Vanderzwalmen P; Schoysman R; Makedos G
Hum Reprod; 2005 Jun; 20(6):1516-20. PubMed ID: 15860501
[TBL] [Abstract][Full Text] [Related]
13. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
Lubin V; Charbonnel B; Bouchard P
Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
[TBL] [Abstract][Full Text] [Related]
14. Outcome of cryopreserved pronuclear oocytes obtained after ovarian stimulation with either HMG or recFSH and the GnRH-antagonist cetrorelix.
Asimakopoulos B; Nikolettos N; Al-Hasani S
Reprod Biomed Online; 2002; 5 Suppl 1():52-6. PubMed ID: 12537782
[TBL] [Abstract][Full Text] [Related]
15. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
16. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
17. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.
Kolibianakis EM; Zikopoulos K; Schiettecatte J; Smitz J; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
Hum Reprod; 2004 Nov; 19(11):2490-6. PubMed ID: 15319383
[TBL] [Abstract][Full Text] [Related]
18. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
19. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
[TBL] [Abstract][Full Text] [Related]
20. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.
Diedrich K; Ludwig M; Felberbaum RE
Semin Reprod Med; 2001 Sep; 19(3):213-20. PubMed ID: 11679902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
